Cargando…

Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action

Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce...

Descripción completa

Detalles Bibliográficos
Autores principales: Kochanowska, Anna, Rusztyn, Przemysław, Szczerkowska, Karolina, Surma, Stanisław, Gąsecka, Aleksandra, Jaguszewski, Miłosz J., Szarpak, Łukasz, Filipiak, Krzysztof J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380892/
https://www.ncbi.nlm.nih.gov/pubmed/37504524
http://dx.doi.org/10.3390/jcdd10070268
_version_ 1785080307551043584
author Kochanowska, Anna
Rusztyn, Przemysław
Szczerkowska, Karolina
Surma, Stanisław
Gąsecka, Aleksandra
Jaguszewski, Miłosz J.
Szarpak, Łukasz
Filipiak, Krzysztof J.
author_facet Kochanowska, Anna
Rusztyn, Przemysław
Szczerkowska, Karolina
Surma, Stanisław
Gąsecka, Aleksandra
Jaguszewski, Miłosz J.
Szarpak, Łukasz
Filipiak, Krzysztof J.
author_sort Kochanowska, Anna
collection PubMed
description Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce cardiovascular events, all-cause mortality, and hospitalization rates. Some of these effects may be due to their impact on serum uric acid (SUA) concentration. Findings from nine meta-analyses showed that, indeed, SGLT2is significantly reduce SUA. The data on the drug- and dose-dependency of this effect were inconclusive. Several factors alternating the beneficial effects of SGLT2is on SUA, such as glycated hemoglobin concentration (HbA1c), presence of diabetes, and baseline SUA level, were described. Even though there is a consensus that the lowering of SUA by SGLT2is might be due to the increased urinary excretion rate of uric acid (UEUA) rather than its altered metabolism, the exact mechanism remains unknown. The influence of SGLT2is on SUA may not only be used in gout treatment but may also be of huge importance in explaining the observed pleiotropic effects of SGLT2is.
format Online
Article
Text
id pubmed-10380892
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103808922023-07-29 Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action Kochanowska, Anna Rusztyn, Przemysław Szczerkowska, Karolina Surma, Stanisław Gąsecka, Aleksandra Jaguszewski, Miłosz J. Szarpak, Łukasz Filipiak, Krzysztof J. J Cardiovasc Dev Dis Review Sodium–glucose cotransporter 2 inhibitors (SGLT2is) are glucose-lowering agents whose positive impact on cardiovascular risk has been described extensively. Not only do they influence lipid profile, blood pressure, atherosclerosis risk, hemoglobin level, and insulin resistance, but they also reduce cardiovascular events, all-cause mortality, and hospitalization rates. Some of these effects may be due to their impact on serum uric acid (SUA) concentration. Findings from nine meta-analyses showed that, indeed, SGLT2is significantly reduce SUA. The data on the drug- and dose-dependency of this effect were inconclusive. Several factors alternating the beneficial effects of SGLT2is on SUA, such as glycated hemoglobin concentration (HbA1c), presence of diabetes, and baseline SUA level, were described. Even though there is a consensus that the lowering of SUA by SGLT2is might be due to the increased urinary excretion rate of uric acid (UEUA) rather than its altered metabolism, the exact mechanism remains unknown. The influence of SGLT2is on SUA may not only be used in gout treatment but may also be of huge importance in explaining the observed pleiotropic effects of SGLT2is. MDPI 2023-06-22 /pmc/articles/PMC10380892/ /pubmed/37504524 http://dx.doi.org/10.3390/jcdd10070268 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kochanowska, Anna
Rusztyn, Przemysław
Szczerkowska, Karolina
Surma, Stanisław
Gąsecka, Aleksandra
Jaguszewski, Miłosz J.
Szarpak, Łukasz
Filipiak, Krzysztof J.
Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
title Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
title_full Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
title_fullStr Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
title_full_unstemmed Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
title_short Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
title_sort sodium–glucose cotransporter 2 inhibitors to decrease the uric acid concentration—a novel mechanism of action
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380892/
https://www.ncbi.nlm.nih.gov/pubmed/37504524
http://dx.doi.org/10.3390/jcdd10070268
work_keys_str_mv AT kochanowskaanna sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction
AT rusztynprzemysław sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction
AT szczerkowskakarolina sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction
AT surmastanisław sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction
AT gaseckaaleksandra sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction
AT jaguszewskimiłoszj sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction
AT szarpakłukasz sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction
AT filipiakkrzysztofj sodiumglucosecotransporter2inhibitorstodecreasetheuricacidconcentrationanovelmechanismofaction